Acute pharmacodynamic responses to exenatide:

Drug-induced increases in insulin secretion and glucose effectiveness

Simeon I. Taylor MD, PhD[1] | May E. Montasser PhD[1] | Ashley H. Yuen MD[1] |

Hubert Fan[2] | Zhinoososadat Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] |

Braxton D. Mitchell PhD, MPH[1] | Alan R. Shuldiner MD[1] | Ranganath Muniyappa MD PhD[2] |

Elizabeth A. Streeten MD[1] | Amber L. Beitelshees PharmD, MPH[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA

[2] Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Email: staylor2@som.umaryland.edu

Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

Trial registration: NCT05762744 (clinicaltrials.gov)

Study review and approval: Institutional Review Board of the University of Maryland Baltimore

ABSTRACT

Background: GLP1R agonists provide multiple benefits to patients with type 2 diabetes – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.

Methods: Exenatide (5 µg, sc) or saline (0.2 mL, sc) was administered to 62 healthy volunteers. Frequently sampled intravenous glucose tolerance tests were conducted to assess the impact of exenatide on insulin secretion and insulin action. This pilot study was designed as a crossover study in which participants received exenatide and saline in random order.

Results: Exenatide increased first phase insulin secretion 1.9-fold ($p=1.9x10^{-9}$) and accelerated the rate of glucose disappearance 2.4-fold ($p=2x10^{-10}$). Minimal model analysis demonstrated that exenatide increased glucose effectiveness (S_g) by 32% (p=0.0008) but did not significantly affect insulin sensitivity (S_i). The exenatide-induced increase in insulin secretion made the largest contribution to inter-individual variation in exenatide-induced acceleration of glucose disappearance while inter-individual variation in the drug effect on S_g contributed to a lesser extent (β=0.58 or 0.27, respectively).

Conclusions: This pilot study provides validation for the value of an FSIGT (including minimal model analysis) to provide primary data for our ongoing pharmacogenomic study of pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative assessments of GLP1R agonists' effects on glucose metabolism: first phase insulin secretion, glucose disappearance rates, and glucose effectiveness.

Registration: NCT02462421 (clinicaltrials.gov)

Funding: American Diabetes Association (1-16-ICTS-112); National Institute of Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, P30DK072488)

49 # 1 | Introduction

50 Head-to-head comparative effectiveness studies demonstrate that diabetes drugs are not
51 strongly differentiated with respect to their effectiveness to decrease mean HbA1c [1].
52 Nevertheless, individual patients vary widely in their responses to individual therapies. For
53 example, semaglutide (1.0 mg/wk) decreased HbA1c by an average of 1.64% (SEM ≈ 0.05%;
54 SD ≈ 0.95%) in patients with baseline HbA1c=8.17% [2]. The observed magnitude of standard
55 deviation suggests that some patients experienced little if any decrease in HbA1c while others
56 experienced >2.5% HbA1c-lowering. This inter-individual variation may result from genetics,
57 environment, or interplay between both factors. Pharmacogenetics has potential to guide
58 treatment decisions, enabling clinicians to recommend optimal therapy for individual patients
59 based on individualized predictors of responsiveness and susceptibility to adverse effects [1].

60 Pharmacogenomic studies have identified genetic variants associated with the magnitude of
61 responses to several diabetes drugs, including metformin, sulfonylureas, and GLP1 receptor
62 agonists [3-7]. While some genetic variants alter a drug's pharmacokinetics, other genetic variants
63 alter pharmacodynamics by altering functions of proteins that mediate drug responses. Although
64 genetic variation in pharmacokinetics may be less relevant for responses to an injectable
65 peptide drug such as exenatide, genetic variants in the *GLP1R* gene have been reported to be
66 associated with pharmacodynamic responses to GLP1 receptor agonists [4-7].

67 We initiated this clinical trial as a pilot and feasibility study for our ongoing genome-wide
68 association study of responses to semaglutide (NCT05071898). Specifically, we conducted
69 frequently sampled intravenous glucose tolerance tests (FSIGT) to assess pharmacodynamic
70 responses to a rapid-acting GLP1R agonist (exenatide): glucose-stimulated insulin secretion
71 and the rate of glucose disappearance (minutes 25-50 in an FSIGT). Herein we summarize
72 pharmacodynamic responses to exenatide in the overall study population as well as in

73 participants who were homozygous for two genetic variants, *GIPR* (p.E354Q; rs1800437) and
74 *GCGR* (p.G40S; rs850763). As expected, exenatide triggered a substantial increase in glucose-
75 stimulated insulin secretion. Variation in the magnitude of the increase in glucose-stimulated
76 insulin secretion accounted for over half the inter-individual variation in the magnitude of
77 exenatide-triggered acceleration of glucose disappearance. Although exenatide did not trigger a
78 statistically significant increase in insulin sensitivity (S_i) as estimated by Bergman's minimal
79 model [8], acute administration of a single dose of exenatide triggered a 32% increase in glucose
80 effectiveness (S_g). Several mechanisms have been reported previously to contribute to effects
81 of GLP1R agonists on glucose metabolism [9-11]: (a) enhancement of glucose-stimulated insulin
82 secretion; (b) delayed gastric emptying and slowed intestinal motility; (c) weight loss; and (d)
83 increased glucose effectiveness [12-15].

84

85 # 2 | Methods

86 ## 2.1 | Study population: recruitment and screening

87 The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the
88 early 1700's. There are currently ~40,000 Old Order Amish individuals in the Lancaster area.
89 University of Maryland School of Medicine researchers have been studying genetic
90 determinants of cardiometabolic health in this population since 1993. To date, ~10,000 Amish
91 adults participated in one or more studies as part of the Amish Complex Disease Research
92 Program (http://www.medschool.umaryland.edu/endocrinology/Amish-Research-Program/).
93 These studies generated a genotype database that was used to identify individuals with any of
94 three genotypes who were eligible for our clinical trial: (a) homozygotes for a missense variant
95 in *GIPR* (p.E354Q; rs1800437); (b) homozygotes for a missense variant in *GCGR* (p.G40S;
96 rs850763); and (c) individuals who were homozygous for the "wild type" major alleles of *GIPR*
97 and *GCGR*. A research nurse, accompanied by a member of the Amish community, made home
98 visits to invite individuals to participate in the study. If they expressed interest, the study was
99 explained in detail; potential participants were invited to sign an informed consent form.
100 Thereafter, the research nurse obtained a medical history; measured height, weight and blood
101 pressure; and obtained blood samples for screening laboratory tests (hematocrit, fasting plasma
102 glucose, serum creatinine, serum AST, serum ALT, plasma TSH, and HbA1c). The study
103 included two frequently sampled intravenous glucose tolerance tests (FSIGT).

104 ## 2.2 | Study design: overview

105 The study was designed as a crossover study in which healthy individuals were
106 randomized between administration of exenatide (5 µg, sc) or saline (0.2 mL, sc).
107 Fifteen minutes after the injections, participants underwent a frequently sampled
108 intravenous glucose tolerance test (FSIGT). A second FSIGT was conducted 5-28 days

later; each participant received the treatment (either saline or exenatide) not administered for the first FSIGT. All procedures were reviewed and approved by the University of Maryland Baltimore IRB.

2.3 | Frequently sampled intravenous glucose tolerance tests

After an overnight fast, participants were transported to the Amish Research Clinic where FSIGTs were performed [8,16-18]. Two 20-gauge catheters were placed in antecubital veins through which normal saline (60 mL/hr) was administered – one for intravenous administration of D50W and one for obtaining blood samples. The infusion was stopped at times when blood samples were withdrawn. To minimize dilution of blood, small amounts of blood were discarded prior to obtaining blood samples. After placement of intravenous catheters, participants received subcutaneous injections of either exenatide (5 μg, sc) or saline (0.2 mL, sc). Fifteen minutes after the subcutaneous injections, an intravenous bolus of glucose (0.3 g/kg) was infused over two minutes. Thirty-one timed blood samples were obtained between -10- and +180-minutes relative to the i.v. glucose infusion [18]. Plasma samples were used to assay levels of glucose and insulin.

2.4 | Power calculations

We aimed to recruit 24 research participants for each of the three genotypes. We estimated that these recruitment targets provided 80% power (with p=0.05) to detect association with a 35% change in first-phase insulin secretion and a 25% change in glucose disappearance rate for homozygous variant compared to homozygous wild-type individuals. However, the clinical trial was terminated early when it became apparent that we would not meet our recruitment targets within the available budget.

2.5 | Eligibility criteria

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent, at least 18 years old, and have BMI between 18-40 kg/m^2. Exclusion criteria are summarized in the Supplementary Appendix.

2.5 | Clinical chemistry

Processing of blood samples and laboratory methods are summarized in the Supplementary Appendix.

2.6 | Data and statistical analyses

We established two primary end points: drug effects on (a) first phase insulin secretion and (b) glucose disappearance rate. Fig. 1 presents untransformed data on plasma levels of insulin and glucose. Tables 1 and 2 present analyses of logarithmic transformation of data on AIR_g, S_i, S_g, and glucose disappearance rates because the untransformed data were not normally distributed. Data in all the other Figures and Tables were inverse normally transformed and multiplied by SD to have effect size in real units; all analyses in those Figures and Tables were adjusted for age, sex, and BMI. Genetic association analysis (Table S3) was performed using linear mixed models to account for familial correlation using the kinship relationship matrix as implemented in the Mixed Model Analysis for Pedigree and population [https://mmap.github.io/]. Multiple regression analysis was conducted using Excel. Minimal model analyses were conducted as described elsewhere [17-19]. Statistical significance was assessed using a paired t-test. Although a p-value of $p<0.05$ was defined as the threshold for nominal statistical significance, a more stringent threshold (e.g., $p<0.001$) may be appropriate to account for multiple comparisons.

153 # 3 | Results

154 ## 3.1 | Disposition and adverse events

155 Research participants' baseline characteristics are summarized in Table S1. Disposition of
156 participants and adverse events are summarized in Fig. S1. Seventy-eight individuals were
157 enrolled in this clinical trial between June, 2016 - November, 2018. Sixty-two participants
158 completed frequently sampled intravenous glucose tolerance tests.

159 ## 3.2 | Intravenous glucose tolerance tests: impact of exenatide

160 Intravenous administration of glucose triggered prompt increases in plasma levels of glucose
161 and insulin (Fig. 1). Plasma glucose achieved a peak at ~4 min – after which time glucose levels
162 decreased. Administration of exenatide augmented insulin secretion. We defined indices to
163 quantitate exenatide's direct effect on glucose-simulated insulin secretion and exenatide's
164 indirect effect on the rate of glucose disappearance (Table S2). As illustrated by the time course
165 of insulin levels in exenatide-treated individuals (Fig. 1), insulin secretion was biphasic.
166 Consistent with published literature [20,21] , the area-under-the-curve (AUC) between 0-10 min
167 provides an index of first phase insulin secretion (Table S2). We used AUC between 10-50 min
168 as an index of second phase insulin secretion. The "cut-off" point at 10 min was selected
169 because that was the time of the nadir separating the first peak of insulin levels from the second
170 peak in exenatide-treated individuals (Fig. 1). The higher plasma insulin levels observed in
171 exenatide-treated individuals accelerated the rate at which glucose levels declined. During the
172 time interval between 25-50 min, the plot of log(glucose) versus time approximates a straight
173 line. We used the slope of that line as an index of the rate at which glucose disappeared from
174 the circulation (Table S2) [20]. Exenatide triggered statistically significant increases in the areas
175 under the curve (AUCs) for first phase (~1.9-fold; $p=1.9x10^{-9}$; Fig. S2) and second phase (~3.5-
176 fold; $p=1x10^{-9}$) insulin secretion as well as the rate at which plasma glucose levels decreased

177 (~2.4-fold; $p=2x10^{-10}$; Fig. S2). Values for first phase and second phase insulin secretion were
178 closely correlated (r=0.46, p=0.0005 for placebo data; r=0.57, $p=5.4x10^{-6}$ for data after
179 administration of exenatide) (Fig. S3).

180 Because curves describing time courses for mean glucose levels in the placebo and exenatide
181 studies are essentially superimposable during the first ten minutes (Fig. 1), the drug effect on
182 first phase insulin secretion likely represents a direct effect of exenatide. In contrast, exenatide's
183 effect on second phase insulin secretion (10-50 min) likely reflects a balance between
184 exenatide's positive direct effect on insulin secretion and the negative impact of lower glucose
185 levels tending to decrease insulin secretion. Accordingly, we have emphasized first phase
186 insulin secretion to assess the correlation between insulin secretion and the rate of glucose
187 disappearance. The rate of glucose disappearance (as defined in Table 1) was correlated with
188 first phase insulin secretion (r=0.74, $p=2.4 \times 10^{-10}$ for placebo data; r=0.63, $3.4x10^{-7}$ for data
189 after administration of exenatide) (Fig. 2AB). As illustrated in the histograms (Fig. S4), we
190 observed substantial inter-individual variation in indices for drug effects on both stimulation of
191 insulin secretion and acceleration of glucose disappearance. While exenatide exerted little or no
192 effect in some individuals, greater than 5-fold increases were observed in other individuals.

193 3.2 | Intravenous glucose tolerance tests: exenatide increases glucose effectiveness

194 Exenatide's effect on the rate of glucose disappearance was correlated with the magnitude of
195 exenatide's effect on insulin secretion (r=0.70; $p=9.2x10^{-9}$) (Fig. 2C). The correlation coefficient
196 suggests that inter-individual variation in the magnitude of exenatide's direct effect on insulin
197 secretion explains approximately half of the observed variance in the magnitude of exenatide's
198 indirect effect on the rate of glucose disappearance. Accordingly, we searched for other factors
199 that might have contributed to variation in the effect of exenatide to accelerate glucose
200 disappearance. We applied Bergman's minimal model [10,16] to estimate insulin sensitivity (S_i),
201 glucose effectiveness (S_g), and disposition index (DI) (Table 1). Although acute administration of

202 exenatide appeared not to alter insulin sensitivity (p=0.36), exenatide treatment increased
203 glucose effectiveness by 32% (p=0.0008), acute insulin response to glucose by 94% ($p=2.3x10^{-}$
204 ^{10}) and disposition index by 95% ($p=2.0x10^{-6}$). The rate of glucose disappearance was
205 significantly correlated with glucose effectiveness for data from both placebo studies (r=0.50,
206 p=0.0001; Fig. 3) and exenatide studies (r=0.66, $p=5.4x10^{-8}$; Fig. 3). We conducted multiple
207 regression analyses to further investigate inter-relationships among the parameters of the
208 minimal model in the context of acute administration of exenatide. In the placebo state, variation
209 in S_i and acute insulin response to glucose (AIR_g) both made similar magnitude contributions to
210 inter-individual variation in the rate of glucose disappearance. An increase of 1 standard
211 deviation unit (SDU) in each of these parameters was associated with an increase of ~0.4 SDU
212 in the rate of glucose disappearance (Table 2). Inter-individual variation in glucose effectiveness
213 made a smaller contribution (i.e., 0.2 SDU increase in glucose disappearance rates for each
214 SDU increase in S_g) (Table 2). After exenatide administration, variation in all three parameters
215 also contributed, but the effect of variation in AIR_g predominated (an increase of 0.61 SDU in the
216 rate of glucose disappearance per 1 SDU increase in insulin secretion); the impact of variations
217 in insulin sensitivity and glucose effectiveness were smaller (Table 2). Variation in the
218 magnitude of the drug effect on insulin secretion was the principal determinant of the magnitude
219 of the drug effect on the rate of glucose disappearance. In addition, an increase of 1 SDU in the
220 drug effect on AIR_g was associated with an increase of 0.58 ± 0.12 SDU in the magnitude of the
221 drug effect for the rate of glucose disappearance ($p=7.2 \times 10^{-7}$) (Table 2).

222 ## 3.3 | Effect of genotype

223 This pilot study was designed to test the hypothesis that missense variants in two candidate
224 genes (*GCGR* and *GIPR*) might be associated with pharmacodynamic responses to GLP1
225 receptor agonists. Table S3 compares pharmacodynamic responses to exenatide among three
226 groups of people: (a) individuals who are homozygous for the major alleles of both genes; (b)

227 homozygotes for the G40S variant of *GCGR* (rs1801483) [22,23]; and (c) homozygotes for the
228 E354Q variant of *GIPR* (rs1800437) [24-26] (Table S3). Four co-primary endpoints were pre-
229 specified: association of genotype (either G40S-*GCGR* or E354Q-*GIPR*) with the magnitude of
230 drug effect (i.e., either exenatide-induced augmentation of first phase insulin secretion or
231 exenatide-induced acceleration of the rate of glucose disappearance). We did not observe
232 statistically significant associations between any of the genetic variants and either of the
233 endpoints.

234

235 # 4 | Discussion

236 Pharmacogenomic research has utilized varied approaches – including acute studies in healthy
237 volunteers assessing acute pharmacodynamic endpoints [3,27] and chronic studies in disease
238 patients assessing routine clinical endpoints such as HbA1c [28]. Short-term studies in healthy
239 volunteers offer several methodological advantages – for example, minimization of confounding
240 factors caused by co-existing diseases and effects of changing co-medications during the
241 course of the study. This pilot study provided an opportunity to validate pharmacodynamic
242 endpoints for our currently ongoing genome-wide association study of the genetics of
243 pharmacodynamic responses to a GLP1 receptor agonist (NCT05071898). As exemplified by
244 the usual stepwise approach to drug development, it can be useful to conduct pilot studies to
245 validate methods and analytic approaches before initiating a larger clinical trial. Our results
246 confirm the existence of substantial inter-individual variation in pharmacodynamic responses to
247 exenatide – ranging from no significant increase to a 5- to 6-fold increase for glucose-sensitive
248 insulin secretion or acceleration of glucose disappearance, respectively. The wide range of
249 inter-individual variation in the magnitude of drug response emphasizes the potential value of
250 identifying genetic variants to predict an individual's pharmacological response and provide
251 guidance to physicians in selecting the best diabetes drug for each individual patient.

252 FDA-approved prescribing information for GLP1R agonists identifies several important clinical
253 benefits for this class of drugs – including, HbA1c-lowering in patients with type 2 diabetes,
254 weight loss in overweight/obese patients, and decreasing major adverse cardiovascular events
255 in patients with type 2 diabetes [29-31]. Our clinical trial assessed drug-induced acceleration of
256 glucose disappearance in healthy non-diabetic individuals, which is mechanistically related to
257 drug-induced HbA1c lowering in patients with type 2 diabetes. Mediation analysis of the
258 LEADER cardiovascular outcome trial suggested that ~90% of liraglutide's beneficial impact on
259 cardiovascular risk reduction was mediated by the drug-induced decrease in HbA1c [32]. This

260 suggests that genetic variants associated with glycemic effects may also contribute to predicting
261 the magnitude of cardiovascular risk reduction. A similar conclusion was reached in a
262 comparative effectiveness analysis comparing different GLP1R agonists. The drugs providing
263 the largest HbA1c-lowering also provided the greatest cardioprotection [33,34].

264 4.1 | Acute exenatide-induced acceleration of glucose disappearance: mechanisms

265 Exenatide increased the magnitude of the glucose-induced increase in insulin secretion by 1.9-
266 fold for 1st phase insulin secretion, by 3.5-fold increase for 2nd phase insulin secretion, and by
267 2.1-fold increase for the rate of glucose disappearance (Figs. 1 and S2; Table 1). Furthermore,
268 exenatide caused a 32% increase in mean glucose effectiveness (S_g) but did not induce a
269 significant change in insulin sensitivity (Table 1). The impact of the exenatide-induced increase
270 in S_g is supported by the observation that rates of glucose disappearance were correlated with
271 the magnitude of S_g in both placebo studies and studies conducted after participants received
272 exenatide (Fig. 3). Multiple regression analysis revealed that inter-individual variation in the
273 magnitudes of glucose-stimulated insulin secretion and insulin sensitivity appeared to contribute
274 significantly to inter-individual variation in the rate of glucose disappearance in both placebo
275 studies and studies conducted after participants received exenatide (Table 2). Thus, although
276 exenatide does not exert an acute effect on insulin sensitivity, pre-existing inter-individual
277 variation in S_i does contribute significantly to inter-individual variation in rates of glucose
278 disappearance both at baseline and in the exenatide-treated states (Table 2). Notwithstanding
279 smaller contributions from S_g and S_i, inter-individual variation in the magnitude of exenatide-
280 induced increase in glucose-sensitive insulin secretion (AIR_g) was quantitatively the most
281 important determinant of the magnitude of the drug-induced increase in glucose disappearance
282 (Table 2); a change of 1 SDU in the drug effect on AIR_g was associated with a 0.58 SDU in the
283 drug effect on the rate of glucose disappearance. These data on effects of exenatide on sub-
284 phenotypes (i.e., insulin secretion and glucose disappearance rate) are generally similar to what

285 has been reported for liraglutide and lixisenatide [20,21] with the exception that lixisenatide was
286 reported not to induce a statistically significant increase in 2nd phase insulin secretion in healthy
287 individuals [21].

288 The term "glucose effectiveness" refers to insulin-independent mechanisms whereby glucose
289 concentrations enhance glucose utilization [8]. The precise physiological mechanisms mediating
290 glucose effectiveness are not completely understood [8]. There has been discussion about
291 challenges in estimating glucose effectiveness from data derived from intravenous glucose
292 tolerance tests. For example, it has been suggested that higher levels of insulin secretion may
293 lead to higher mathematical estimates of glucose effectiveness; it has been challenging to
294 identify detailed mechanisms accounting for these higher estimates of S_g [15,34]. In any case, it is
295 theoretically possible that the exenatide-induced increase in insulin secretion may contribute to
296 the larger mathematical estimates of S_g. Bergman [8] has suggested that glucose effectiveness
297 may reflect hepatic glucose uptake and metabolism (mediated by GLUT2 and glucokinase). As
298 GLP1 receptor agonists have been reported to suppress glucagon levels [11], this might provide
299 an endocrine mechanism whereby exenatide might exert an indirect effect on hepatic glucose
300 metabolism. However, to the extent that effects of exenatide on glucagon secretion by α-cells
301 might be mediated at least in part by paracrine β-cell insulin secretion, such an effect would not
302 necessarily be classified as being insulin-independent. In any case, further research will be
303 required to elucidate physiological mechanisms mediating acute effects of GLP1 receptor
304 agonists on glucose effectiveness.

305 ## 4.2 | Pharmacogenomic candidate genes

306 A missense variant in the *GLP1R* gene (rs6923761; p.T149M) has previously been reported to
307 be associated with a diminished response to GLP1 receptor agonists [6,7,35] . We have not
308 detected this variant in DNA sequences in the Old Order Amish. Recent literature has
309 suggested the existence of positive crosstalk among GLP1, GIP, and glucagon with respect to

310 their beneficial effects on insulin secretion and weight loss [36] . These considerations led to the
311 design of tirzepatide – a recently approved “twincretin” combining agonist activity against both
312 GLP1R and GIPR [37]. Based on these data, we hypothesized that there might be
313 pharmacologically relevant interactions between an exogenous GLP1R agonist and
314 endogenous glucagon or GIP. To test these hypotheses, we recruited individuals who are
315 homozygous for two relatively common missense variants: rs1801483 (p.G40S) in *GCGR* and
316 rs1800437 (p.E354Q) in *GIPR*. The p.E354Q variant in *GIPR* has been reported to enhance
317 agonist-induced receptor desensitization – potentially leading to resistance to the effect of GIP
318 agonists. Furthermore, this genetic variant in *GIPR* has been reported to be associated with
319 increased plasma levels of GIP as well as various anthropometric and glycemic traits [38]. The
320 p.G40S variant in *GCGR* has been reported to impair signaling through β-arrestin-1 [23]. This
321 p.G40S variant in *GCGR* has been reported to be associated with diabetes [22], but this finding
322 seems not to be reproducible [39].

323 Although we observed numerical decreases of 20-25% in the magnitude of the effect of
324 exenatide-induced effect on first phase glucose-stimulated insulin secretion in homozygotes for
325 variants in both *GIPR* (rs1800437) and *GCGR* (rs1801483), these numerical differences were
326 not statistically significant. We encountered greater than expected difficulty in recruiting
327 research participants with the genotypes of interest. The small size of the study population
328 creates uncertainty about the interpretation of our observations – i.e., whether the statistically
329 insignificant numerical trends toward a decrease in the response to exenatide might possibly
330 represent type II error (incorrect rejection of a false null hypothesis). Further research will be
331 required to resolve these uncertainties. Whether or not the missense variant in *GIPR* alters the
332 response to a selective GLP1R agonist, it would be of interest to determine whether the variant in
333 *GIPR* is associated with variation in response to peptides possessing GIPR agonist activity
334 (including tirzepatide) [37].

335 **ACKNOWLEDGEMENTS**

336 We gratefully acknowledge funding provided by the American Diabetes Association (grant
337 number 1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease
338 (R01DK130238, T32DK098107, and P30DK072488). We also gratefully acknowledge
339 contributions of the research participants and the skilled staff at the Amish Research Clinic for
340 their critical roles in making this study possible. We are grateful to Mary Pavlovich, Melanie
341 Daue, and Kathy Ryan for their help with database management. Dr. Laura Yerges-Armstrong
342 provided genotype data enabling us to identify individuals to be invited to participate in this
343 genotype-guided recruitment study.

344

345 **AUTHORS' CONTRIBUTIONS**

346 *Conception of the clinical trial and PI for the grant from the American Diabetes Association grant*

347 *(*1-16-ICTS-112*)*: SIT

348 *Acquisition and analysis of data*: ALB, AHY, MEM, EAS, SIT, HBW, ZSY

349 *Minimal model analysis of FSIGT data*: RM, HF

350 *Establishment of Old Order Amish genotype database*: BDM, ARS

351 *Preparation of first draft of manuscript*: SIT

352 *Revising and approving final version of manuscript*: all authors

353 *Overall accountability for all aspects of work*: SIT

354

355 **Competing Interests**

356 SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of
357 royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an
358 employee of Regeneron Genetics Center. BDM and MEM receive grant support from
359 Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support
360 from funds provided by RGC. ALB, ZSY, RM, and HF declare no competing interests.

361 **Table 1. Parameters from minimal model analyses.** This Table summarizes data from 45
362 frequently sampled intravenous glucose tolerance tests conducted after research participants
363 received either saline (placebo) or exenatide. Data are presented as means ± SEM. The first
364 five rows present analyses of untransformed data whereas the next five rows present analyses
365 of logarithmically transformed data. Paired t-tests were conducted on the logarithmically
366 transformed data; two-sided p-values are presented in the last column of the Table. Rates of
367 glucose disappearance were calculated as described in Table S2.

Parameter	Placebo	Exenatide	p-value
Insulin sensitivity (S_i) [a]	6.80 ± 0.60	7.07 ± 0.58	
Glucose effectiveness (S_g) [b]	0.0139 ± 0.0010	0.0183 ± 0.010	
Acute insulin response (AIR_g) [c]	243 ± 24	472 ± 56	
Disposition index (DI)	1454 ± 157	2833 ± 288	
Glucose disappearance rate	506 ± 31	1060 ± 70	
Log (S_i)	0.73 ± 0.05	0.78 ± 0.04	0.36
Log (S_g)	-1.92 ± 0.04	-1.76 ± 0.03	0.0008
Log (AIR_g)	2.31 ± 0.04	2.58 ± 0.04	2.3×10^{-10}
Log (DI)	3.04 ± 0.05	3.36 ± 0.04	2.0×10^{-6}
Log (glucose disappearance rate)	2.66 ± 0.03	2.96 ± 0.04	1.4×10^{-13}

368

369 [a] units: $10^{-4} \cdot min^{-1}$ / [μU/mL]

370 [b] units: min^{-1}

371 [c] units: $\mu U \cdot mL^{-1} \cdot min^{-1}$

372

Table 2. Relative contributions to the rate of glucose disappearance: beta coefficients from multiple regression of parameters derived from minimal model analysis. The Table presents results of multiple regression analyses with three independent variables derived from minimal model analysis of frequently sampled intravenous glucose tolerance tests. The first two columns present data on logarithmically transformed values of insulin sensitivity (S_i), glucose effectiveness (S_g), and acute insulin response to glucose (AIR_g) in studies where participants received either saline (placebo) or exenatide. The last column presents analysis of logarithmically transformed data on effects of exenatide (i.e., "drug effects" calculated as specified in Table S2) on insulin sensitivity (S_i), glucose effectiveness (S_g), and acute insulin response to glucose (AIR_g). in each analysis, the dependent variable was the rate of glucose disappearance as defined in Table S2. Beta values are expressed in standard deviation units (SDU) – i.e., the change in the dependent variable relative to the change in the independent variable in SDU. The last row of the Table presents the overall two-sided p-value for each multiple regression model as calculated using Excel. The footnotes indicate two-sided p-values for each of the coefficients. Units for the minimal model parameters are summarized in Table 1.

Parameter	Placebo	Exenatide	Drug Effect
Insulin sensitivity (S_i)	0.39 ± 0.16^{d}	0.37 ± 0.09^{c}	0.14 ± 0.11^{e}
Glucose effectiveness (S_g)	0.20 ± 0.16^{gd}	0.21 ± 0.09^{f}	0.27 ± 0.13^{g}
Acute insulin response (AIR_g)	0.41 ± 0.15^{c}	0.61 ± 0.13^{b}	0.58 ± 0.12^{a}
p-value	0.009	1.9×10^{-6}	5.3×10^{-8}

[a] $p=7.2 \times 10^{-7}$; [b] p=0.0004; [c] p=0.01 [d] p=0.02; [e] p=0.03; [f] p=0.15; [g] p=0.23

394 **Figure 1. Exenatide enhances insulin secretion and accelerates the rate of glucose**
395 **disappearance decrease in frequently sampled intravenous glucose tolerance tests**
396 **(FSIGT).**

397 Fifty-three non-diabetic healthy volunteers participated in a randomized crossover study of
398 exenatide (N=53). After an overnight fast, participants were randomly assigned to receive either
399 exenatide (5 µg, s.c.; solid circles) or saline (0.2 mL, s.c.; open circles). The FSIGT was initiated
400 15 min after the s.c. injection by administration of glucose (0.3 g/kg, i.v.) over two minutes.
401 Blood samples were obtained for measurement of plasma glucose (panel A) and plasma insulin
402 (panel B) over the course of 180 min after glucose administration as described in the Methods
403 section [8,16-18]. After a washout period of 5-28 days, a second FSIGT was conducted in which the
404 participant received the treatment (either saline or exenatide) not administered for the first
405 FSIGT.

406

407
408



409
410

411

412

413 **Figure 2. Correlations between the rate of glucose disappearance and first phase insulin**
414 **secretion**. Glucose-stimulated insulin secretion accelerates the rate of glucose disappearance,
415 which in turn provides an "off" signal for insulin secretion. This analysis demonstrates that the
416 index for the rate of glucose disappearance between 25-50 min (Table 1) is correlated with the
417 index for first phase insulin secretion (Table 1) in both the placebo-FSIGT (panel A; r=0.74;
418 $p=2.4x10^{-10}$) and the exenatide-FSIGT (panel B; r=0.63; $p=3.4x10^{-7}$). Indices for effects of
419 exenatide on first phase insulin secretion and the rate of glucose disappearance are defined in
420 Table 1. The index for exenatide-induced acceleration of glucose disappearance is correlated
421 with the index for exenatide-induced insulin secretion (panel C; r=0.70; $p=9.2x10^{-9}$). Areas under
422 the curve for 1st phase insulin secretion are expressed in the following units: (μU/mL) · min.

423

424

425



426 **Figure 3. Correlation of rate of glucose disappearance with glucose effectiveness (S_g).**

427 Rates of glucose disappearance (vertical axis) are plotted as a function of glucose effectiveness

428 (S_g) (horizontal axis). The correlation coefficients and p-values are indicated in the Figures for

429 the placebo studies (left panel) and the exenatide studies (right panel). Values of Sg are

430 expressed in the following units: min^{-1}. Rates of glucose disappearance were calculated as

431 summarized in Table S2.



432

433

434 **REFERENCES**

435 1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2
436 diabetes: a patient-centered approach: position statement of the American Diabetes
437 Association (ADA) and the European Association for the Study of Diabetes (EASD).
438 *Diabetes Care.* 2012;35(6):1364-1379.

439 2. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly
440 Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-
441 Week, Open-Label, Randomized Clinical Trial. *Diabetes Care.* 2018;41(2):258-266.

442 3. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin
443 pharmacogenomics: current status and future directions. *Diabetes.* 2014;63(8):2590-2599.

444 4. Pearson ER. Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabet Med.*
445 2021;38(12):e14726.

446 5. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs.
447 *Diabetologia.* 2021;64(6):1201-1212.

448 6. Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1
449 receptor gene associated with greater effect of liraglutide and exenatide on gastric
450 emptying: A pilot pharmacogenetics study. *Neurogastroenterol Motil.* 2018;30(7):e13313.

451 7. Mashayekhi M, Wilson JR, Jafarian-Kerman S, et al. Association of a glucagon-like peptide-
452 1 receptor gene variant with glucose response to a mixed meal. *Diabetes Obes Metab.*
453 2021;23(1):281-286.

454 8. Bergman RN. Origins and History of the Minimal Model of Glucose Regulation. *Front*
455 *Endocrinol (Lausanne).* 2020;11:583016.

456 9. Drucker DJ. The Ascending GLP-1 Road From Clinical Safety to Reduction of
457 Cardiovascular Complications. *Diabetes.* 2018;67(9):1710-1719.

458 10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
459 *Cell Metab.* 2018;27(4):740-756.

460 11. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the
461 Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocr Rev.*
462 2021;42(2):101-132.

463 12. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like
464 peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. *N Engl J Med.*
465 1992;326(20):1316-1322.

466 13. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances
467 glucose tolerance both by stimulation of insulin release and by increasing insulin-
468 independent glucose disposal. *J Clin Invest.* 1994;93(5):2263-2266.

469 14. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on glucose
470 kinetics during somatostatin-induced suppression of insulin secretion in healthy men. *Horm*
471 *Res.* 1998;49(5):221-225.

472 15. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like peptide 1 on non-
473 insulin-mediated glucose uptake in the elderly patient with diabetes. *Diabetes Care.*
474 2001;24(11):1951-1956.

475 16. Beard JC, Bergman RN, Ward WK, Porte D, Jr. The insulin sensitivity index in nondiabetic
476 man. Correlation between clamp-derived and IVGTT-derived values. *Diabetes.*
477 1986;35(3):362-369.

478 17. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance
479 in subjects with IDDM. Discordance between experimental results and minimal model
480 analysis. *Diabetes.* 1994;43(7):890-896.

481 18. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity
482 and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol*
483 *Endocrinol Metab.* 2008;294(1):E15-26.

484 19. Fosam A, Yuditskaya S, Sarcone C, Grewal S, Fan H, Muniyappa R. Minimal Model-Derived
485 Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans. *Diabetes*
486 *Care.* 2021;44(11):2586-2588.

487 20. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and
488 tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in
489 healthy male subjects. *Diabetes Care.* 2002;25(8):1398-1404.

490 21. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory
491 response to intravenous glucose challenge in people with type 2 diabetes--a study in both
492 people with type 2 diabetes and healthy subjects. *Diabetes Obes Metab.* 2014;16(9):793-
493 800.

494 22. Hager J, Hansen L, Vaisse C, et al. A missense mutation in the glucagon receptor gene is
495 associated with non-insulin-dependent diabetes mellitus. *Nat Genet.* 1995;9(3):299-304.

496 23. van der Velden WJC, Lindquist P, Madsen JS, et al. Molecular and in vivo phenotyping of
497 missense variants of the human glucagon receptor. *J Biol Chem.* 2022;298(2):101413.

498 24. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of
499 human incretin receptor missense variants. *J Pharmacol Exp Ther.* 2010;332(1):274-280.

500 25. Gabe MBN, van der Velden WJC, Gadgaard S, et al. Enhanced agonist residence time,
501 internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor
502 desensitization and long-term impairment of the GIP system. *Basic Clin Pharmacol Toxicol.*
503 2020;126 Suppl 6:122-132.

504 26. Mohammad S, Patel RT, Bruno J, Panhwar MS, Wen J, McGraw TE. A naturally occurring
505 GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs
506 GIP control of adipose insulin sensitivity. *Mol Cell Biol.* 2014;34(19):3618-3629.

507 27. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19
508 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA.*
509 2009;302(8):849-857.

510 28. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is
511 associated with glycemic response to metformin. *Nat Genet.* 2016;48(9):1055-1059.

512 29. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in
513 type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.*
514 2019;394(10193):121-130.

515 30. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients
516 with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-1844.

517 31. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes
518 in Type 2 Diabetes. *N Engl J Med.* 2016;375(4):311-322.

519 32. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular Risk Reduction With Liraglutide: An
520 Exploratory Mediation Analysis of the LEADER Trial. *Diabetes Care.* 2020;43(7):1546-1552.

521 33. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet Diabetes*
522 *Endocrinol.* 2018;6(2):83-85.

523 34. Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease
524 risk in type 2 diabetes: A 21st century assessment. *Diabetes Obes Metab.*
525 2022;24(12):2297-2308.

526 35. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and
527 weight in obesity: A randomized clinical and pharmacogenomic trial. *Obesity (Silver Spring).*
528 2022;30(8):1608-1620.

529 36. Capozzi ME, DiMarchi RD, Tschop MH, Finan B, Campbell JE. Targeting the
530 Incretin/Glucagon System With Triagonists to Treat Diabetes. *Endocr Rev.* 2018;39(5):719-
531 738.

532 37. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in
533 Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385(6):503-515.

534 38. Bowker N, Hansford R, Burgess S, et al. Genetically Predicted Glucose-Dependent
535 Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by
536 Distinct Causal Variants in the GIPR Region. *Diabetes.* 2021;70(11):2706-2719.

537 39. Huang X, Orho M, Lehto M, Groop L. Lack of association between the Gly40Ser
538 polymorphism in the glucagon receptor gene and NIDDM in Finland. *Diabetologia.*
539 1995;38(10):1246-1248.

540

Supplementary Appendix

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness

Simeon I. Taylor MD, PhD[1] | May E. Montasser PhD[1] | Ashley H. Yuen MD[1] | Hubert Fan[2] | Zhinoososadat Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] | Braxton D. Mitchell PhD, MPH[1] | Alan R. Shuldiner MD[1] | Ranganath Muniyappa MD PhD[2] | Elizabeth A. Streeten MD[1] | Amber L. Beitelshees PharmD, MPH[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA

[2] Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Email: staylor2@som.umaryland.edu

Funding information

American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

24 # Table of Contents

25 Exclusion criteria p. 3

26 Clinical chemistry p. 4

27 Table S1. Demographics and baseline characteristics of study population p. 5

28 Table S2. Definition of parameters for statistical analyses p. 6

29 Table S3. Interactions of genotype with pharmacodynamic responses to exenatide p. 7

30 Figure S1. CONSORT diagram summarizing disposition of research participants p. 8

31 Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose
32 disappearance in frequently sampled intravenous glucose tolerance tests p. 10

33 Figure S3. Correlations between first and second phase insulin secretion p. 11

34 Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase
35 Insulin secretion and rate of glucose disappearance p. 12

1 | Exclusion Criteria

- Known allergy to exenatide
- History of diabetes, random glucose >200 mg/dL, or HbA1c $\geq$ 6.5%
- Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judged would make interpretation of the results difficult or increase the risk of participation
- Seizure disorder
- Pregnant by self-report or known pregnancy within 3 months of the start of study
- Currently breast feeding or breast feeding within 3 months of the start of the study
- Estimated glomerular filtration rate <60 mL/min/1.73m^2
- Hematocrit <35%
- Liver function tests greater than 2 times the upper limit of normal
- Abnormal TSH
- History of pancreatitis or pancreatic cancer. Personal or family history of medullary carcinoma of the thyroid.

53 ## 2 | Clinical Chemistry

54 Screening blood samples were obtained by a research nurse during home visits and collected in
55 test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for
56 measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for
57 measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for
58 measurement of fasting plasma glucose; red top tube for collecting serum samples. After
59 placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical
60 laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation
61 (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay.
62 Blood samples for the frequently sampled intravenous glucose tolerance test were collected in
63 EDTA-containing purple top tubes for measurement of plasma insulin and in EDTA/oxalate-
64 containing gray top tubes for measurement of plasma glucose. Glucose was measured in
65 duplicate using an YSI glucose analyzer. Insulin was assayed in duplicate following the
66 manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc.

67

68

69 **Table S1. Demographics and baseline characteristics of study population**

Mean ± SEM (range)	Males	Females	Total
N (sample size)	33	21	54
Age (years)	46.0 ± 2.0	52.0 ± 2.1	48.3 ± 1.5
BMI (kg/m^2)	27.3 ± 0.6	28.9 ± 0.8	27.9 ± 0.5
HbA1c (%)	5.51 ± 0.6	5.60 ± 0.7	5.54 ± 0.4
Serum creatinine (mg/dL)	0.88 ± 0.02	0.73 ± 0.02	0.82 ± 0.02
eGFR (mL/min/1.73 m^2)	101.2 ± 2.2	94.5 ± 3.4	98.6 ± 1.9
Hematocrit (%)	43.6 ± 0.4	39.0 ± 0.5	41.8 ± 0.4
Aspartate amino transferase (U/L)	18.5 ± 0.8	17.4 ± 0.9	18.1 ± 0.6
Alanine amino transferase (U/L)	21.0 ± 1.4	17.3 ± 1.1	19.6 ± 1.0

70

71 **Table S2. Definition of parameters for statistical analyses**

Parameter	Definition
1st phase insulin secretion	Area under the curve (AUC) for plasma insulin levels (0-10 min) calculated by trapezoidal rule
2nd phase insulin secretion	Area under the curve for plasma insulin levels (10-50 min) calculated by trapezoidal rule
Glucose disappearance rate	Slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: 1st phase insulin secretion	Logarithm of AUC for 1st phase insulin secretion when participant received exenatide – logarithm of AUC for 1st phase insulin secretion when participant received saline.
Drug effect: 2nd phase insulin secretion	Logarithm of AUC for 2nd phase insulin secretion when participant received exenatide *minus* logarithm of AUC for 2nd phase insulin secretion when participant received saline.
Drug effect: glucose disappearance rate	Glucose disappearance rate when participant received exenatide *minus* the glucose disappearance rate when participant received saline.
Log-transformed glucose disappearance rate	Logarithm of slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: log-transformed glucose disappearance rate	Logarithm of glucose disappearance rate when participant received exenatide *minus* logarithm of the glucose disappearance rate when participant received saline.

72

73 **Table S3. Interactions of genotype with pharmacodynamic responses to exenatide.**

Treatment	Trait	WT	GCGR Homozygotes (rs1801483)	GIPR Homozygotes (rs1800437)
Placebo	**Insulin AUC – 1st phase**	270 ± 35	248 ± 23	322 ± 55
Placebo	**Insulin AUC – 2nd phase**	828 ± 125	753 ± 77	736 ± 99
Placebo	**Glucose disappearance**	3.87 ± 0.24	4.23 ± 0.34	4.58 ± 0.38
Exenatide	**Insulin AUC – 1st phase**	586 ± 75	409 ± 41	606 ± 144
Exenatide	**Insulin AUC – 2nd phase**	3171 ± 51	2205 ± 107	2399 ± 440
Exenatide	**Glucose disappearance**	10.08 ± 0.69	10.68 ± 0.61	10.19 ± 1.03
Drug Effect	**Insulin AUC – 1st phase**	2.41 ± 0.25	1.80 ± 0.19	1.90 ± 0.25
Drug Effect	**Insulin AUC – 2nd phase**	4.07 ± 0.46	3.22 ± 0.27	3.31 ± 0.44
Drug Effect	**Glucose disappearance**	2.94 ± 0.35	2.78 ± 0.35	2.24 ± 0.17

74

75

76

Figure S1. CONSORT diagram summarizing disposition of research participants. Seventy-eight individuals were enrolled in this clinical trial between June, 2016 – November, 2018. Sixty-two participants completed frequenty sampled glucose tolerance tests. Twelve enrollees were excluded for the following reasons (Fig. S1): low hematocrit (N=1), abnormal TSH levels (N=5), abnormal liver function tests (N=1), family history of medullary carcinoma of the thyroid (N=1), primary hyperparathyroidism (N=1), low eGFR (N=1), poor venous access (N=1), and treatment with warfarin (N=1). Thus, 66 individuals were judged to be eligible for the clinical trial. Three individuals changed their minds and withdrew from the study after providing informed consent but before undergoing an intravenous glucose tolerance test; technical challenges during one FSIGT led to withdrawal of an additional participant. The remaining 63 participants completed the study. Ten individuals were excluded from the data base either because of missing data (N=9) or outlier data (N=1). Thus, data from 53 individuals comprised the final database for most of the analyses. Data from eight individuals' placebo FSIGTs could not be analyzed with the Minimal Model softwared because of issues related to data quality. Accordingly, Minimal Model analysis of the FSIGT was based on data from 45 individuals. There were 27 reported adverse events of mild to moderate severity. Two participants reported feeling light-headed or dizzy in the evening after leaving the Amish Research Clinic; these were classified as probably being related to the study. There were 11 events in which a participant's plasma glucose (determined using a glucometer) was <70 mg/dL (52-63 mg/dL) at the end of an FSIGT. Three participants reported symptoms (weakness, lightheadedness, or not feeling well) 60-90 minutes after receiving intravenous glucose, at which time glucometer readings of 42 – 60 mg/dL were obtained. Symptoms resolved quickly in all cases without intervention, and the FSIGT was not terminated. These were judged to be mild in severity and probably caused by the study.


Enrolled in clinical trial
(06/2016 – 11/2018)
78 Healthy Volunteers
Exclusions (12)
Abnormal lab tests
Abnormal thyroid tests (5)
Anemia (1)
Hyperparathyroidism (1)
eGFR <60 mL/min/1.73 m2 (1)
Abnormal liver function tests (1)
Medical history:
Taking warfarin (1)
Poor venous access (1)
Medullary ca. thyroid (family history) (1)
Completed clinical trial
62 Healthy Volunteers
Non-completers
Withdrew consent (3)
Technical difficulty in FSIGT (1)
Missing Data
Missing samples in FSIGT (8)
Minimal model (quality control) (8)
Outlier data (1)
Database for Analysis
53 for FSIGT data
45 for minimal model data
Adverse Events
Headache (9)
Nausea/vomiting (5)
Diarrhea (2)
Glucometer reading <70 mg/dL (11)

Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose disappearance in frequently sampled intravenous glucose tolerance tests. Data are presented as means of data for 53 research participants. The boxes encompass the 2nd and 3rd quartiles; the "whiskers" correspond to the top and bottom quartiles (excluding outliers). "Outliers" are depicted by the closed circles. Statistical significance (calculated using a paired t-test) is indicated on the graphs. Areas under the curve for 1st and 2nd phase insulin secretion are expressed in the following units: (μU/mL) · min.



113 **Figure S3. Correlations between first and second phase insulin secretion**. Intravenous
114 glucose triggers a biphasic response in the FSIGT: first phase insulin secretion (0-10 min) and
115 second phase insulin secretion (10-50 min). Data are plotted as the logarithms of the areas
116 under the curves for first and second phase insulin secretion; placebo studies are plotted in the
117 left panel and exenatide studies in the right panel. Values for correlation coefficients (r) and p-
118 values are indicated in the figure. Areas under the curve for 1st and 2nd phase insulin secretion
119 are expressed in the following units: (μU/mL) · min.



120

121

122

Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase insulin secretion and rate of glucose disappearance. Indices for effects of exenatide on first phase insulin secretion and the rate of glucose disappearance are defined in Table 1. Histograms depicting inter-individual variation are presented in the left panel for first phase insulin secretion and the right panel for the rate of glucose disappearance.